Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics HCS Reader 2004 Upgrade for ArrayScan HCS, Cisbio s HTRF (Homogenous Time-Resolved Fluorescence) Reagents and Cyclic AMP Jumbo Kit, and CyBio s CyBi-Lumax flash HT

Premium

Cellomics said last month that it has launched the HCS Reader 2004 Upgrade, an upgrade package for its ArrayScan HCS instrumentation platform.

The upgrade consists of new software features and ease-of-use improvements, as well as a new shutterless, high-performance camera, which provides increased sensitivity and reliability, Cellomics said. In addition, the upgrade enables access to the V2 versions of Cellomics’ BioApplications, the company said.


Cisbio said last month that as of Jan. 3, all of its HTRF (homogenous time-resolved fluorescence) reagents, including those related to its service offering, will be referenced and delivered under the 384-well, low-volume (20 µL final volume) format.

Cisbio has also launched a new cyclic AMP jumbo kit (100,000 tests) particularly adapted to HTS requirements, the company said.


CyBio this week announced the availability of a new flash luminescence reader that incorporates the CyBi-Lumax flash HT 16-channel dispenser. The new reader is based on CyBio’s 1,536-well flash luminescence detection technology, but has increased throughput, CyBio said.

 

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.